Replies to post #237146 on Biotech Values

[dewophile]

BCMAs are hot (as are bispecifics). It will be interesting to see how this all shakes out in the coming years.
While a weaker drug selinexor does still benefit from a unique MOA but KPTI would benefit from being able to be combined w these drugs vs competing against them (these studies are under way I think